Rosuvastatin for sepsis-associated acute respiratory distress syndrome.

ABSTRACT:

Background

In the acute respiratory distress syndrome (ARDS), inflammation in the lungs and other organs can cause life-threatening organ failure. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) can modulate inflammatory responses. Previous observational studies suggested that statins improved clinical outcomes in patients with sepsis. We hypothesized that rosuvastatin therapy would improve clinical outcomes in critically ill patients with sepsis-associated ARDS.

Methods

We conducted a multicenter trial in which patients with sepsis-associated ARDS were randomly assigned to receive either enteral rosuvastatin or placebo in a double-blind manner. The primary outcome was mortality before hospital discharge home or until study day 60 if the patient was s

SUBMITTER: National Heart, Lung, and Blood Institute ARDS Clinical Trials Network 

PROVIDER: S-EPMC4241052 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature